Log in

Chromadex Stock Price, Forecast & Analysis (NASDAQ:CDXC)

$3.18
+0.10 (+3.25 %)
(As of 11/16/2019 08:00 AM ET)
Today's Range
$3.06
Now: $3.18
$3.30
50-Day Range
$2.81
MA: $3.29
$4.13
52-Week Range
$2.68
Now: $3.18
$4.95
Volume391,500 shs
Average Volume264,924 shs
Market Capitalization$189.46 million
P/E RatioN/A
Dividend YieldN/A
Beta1.35
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and finished products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. Read More…

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDXC
CUSIPN/A
Phone310-388-6706

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.56 million
Book Value$0.46 per share

Profitability

Net Income$-33,320,000.00

Miscellaneous

Employees100
Market Cap$189.46 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive CDXC News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter.


Chromadex (NASDAQ:CDXC) Frequently Asked Questions

What is Chromadex's stock symbol?

Chromadex trades on the NASDAQ under the ticker symbol "CDXC."

How were Chromadex's earnings last quarter?

Chromadex Corp (NASDAQ:CDXC) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.12) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.12). The company earned $12.05 million during the quarter, compared to analyst estimates of $11.66 million. Chromadex had a negative net margin of 74.55% and a negative return on equity of 137.97%. View Chromadex's Earnings History.

When is Chromadex's next earnings date?

Chromadex is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Chromadex.

What price target have analysts set for CDXC?

3 equities research analysts have issued 12 month target prices for Chromadex's shares. Their forecasts range from $6.00 to $7.00. On average, they anticipate Chromadex's stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 109.6% from the stock's current price. View Analyst Price Targets for Chromadex.

What is the consensus analysts' recommendation for Chromadex?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chromadex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chromadex.

What are Wall Street analysts saying about Chromadex stock?

Here are some recent quotes from research analysts about Chromadex stock:
  • 1. According to Zacks Investment Research, "ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. " (8/13/2019)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We apply a 26.6x EV-to-EBITDA multiple applied to our 2020 EBITDA per share estimate of $0.35, discounted back at a 12% rate, which yields a price objective of approximately $7.00 per share." (4/25/2019)

Has Chromadex been receiving favorable news coverage?

Headlines about CDXC stock have trended very negative on Sunday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Chromadex earned a news impact score of -3.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Chromadex.

Are investors shorting Chromadex?

Chromadex saw a increase in short interest in October. As of October 31st, there was short interest totalling 4,300,000 shares, an increase of 11.1% from the September 30th total of 3,870,000 shares. Based on an average daily volume of 231,200 shares, the days-to-cover ratio is currently 18.6 days. Currently, 15.4% of the shares of the stock are short sold. View Chromadex's Current Options Chain.

Who are some of Chromadex's key competitors?

What other stocks do shareholders of Chromadex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chromadex investors own include Tilray (TLRY), Heron Therapeutics (HRTX), TransEnterix (TRXC), Athersys (ATHX), Glu Mobile (GLUU), Axsome Therapeutics (AXSM), CELYAD SA/ADR (CYAD), Mesoblast (MESO), Sorrento Therapeutics (SRNE) and Corbus Pharmaceuticals (CRBP).

Who are Chromadex's key executives?

Chromadex's management team includes the folowing people:
  • Mr. Frank Louis Jaksch Jr., Co-Founder & Exec. Chairman (Age 51)
  • Mr. Robert N. Fried, CEO & Director (Age 59)
  • Mr. Kevin M. Farr, Chief Financial Officer (Age 61)
  • Mr. Ben Shichman, Chief Technology Officer
  • Dr. Matthew Roberts, Chief Scientific Officer & Sr. VP of Innovation

Who are Chromadex's major shareholders?

Chromadex's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Miracle Mile Advisors LLC (0.10%). Company insiders that own Chromadex stock include Frank L Jaksch Jr, Kevin M Farr, Mark J Friedman, River Ventures Ltd Champion, Robert N Fried and Stephen A Block. View Institutional Ownership Trends for Chromadex.

Which institutional investors are selling Chromadex stock?

CDXC stock was sold by a variety of institutional investors in the last quarter, including Miracle Mile Advisors LLC. View Insider Buying and Selling for Chromadex.

How do I buy shares of Chromadex?

Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Chromadex's stock price today?

One share of CDXC stock can currently be purchased for approximately $3.18.

How big of a company is Chromadex?

Chromadex has a market capitalization of $189.46 million and generates $31.56 million in revenue each year. The company earns $-33,320,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Chromadex employs 100 workers across the globe.View Additional Information About Chromadex.

What is Chromadex's official website?

The official website for Chromadex is http://www.chromadex.com/.

How can I contact Chromadex?

Chromadex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company can be reached via phone at 310-388-6706 or via email at [email protected]


MarketBeat Community Rating for Chromadex (NASDAQ CDXC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  437 (Vote Outperform)
Underperform Votes:  494 (Vote Underperform)
Total Votes:  931
MarketBeat's community ratings are surveys of what our community members think about Chromadex and other stocks. Vote "Outperform" if you believe CDXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel